Clinical Pharmacy Program Guidelines for Sandostatin

<table>
<thead>
<tr>
<th>Program</th>
<th>Prior Authorization</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medication</td>
<td>Sandostatin® (octreotide acetate)</td>
</tr>
<tr>
<td>Markets in Scope</td>
<td>Arizona, California, Florida-CHIP, Hawaii, Maryland, Nevada, New Jersey, New York, New York EPP, Ohio, Pennsylvania-CHIP, Rhode Island</td>
</tr>
<tr>
<td>Issue Date</td>
<td>12/2012</td>
</tr>
<tr>
<td>Pharmacy and Therapeutics Approval Date</td>
<td>9/2019</td>
</tr>
<tr>
<td>Effective Date</td>
<td>11/2019</td>
</tr>
</tbody>
</table>

1. **Background:**

Sandostatin (octreotide acetate) is indicated to reduce blood levels of growth hormone and IGF-I (somatomedin C) in acromegaly patients who have had inadequate response to or cannot be treated with surgical resection, pituitary irradiation and bromocriptine mesylate at maximally tolerated doses. It is also indicated for the symptomatic treatment of patients with metastatic carcinoid tumors where it suppresses or inhibits the severe diarrhea and flushing episodes associated with the disease and for the treatment of profuse watery diarrhea associated with VIP-secreting tumors.\(^1,2\)

The NCCN (National Comprehensive Cancer Network) recommends the use of octreotide acetate for the treatment of meningiomas. The NCCN also recommends octreotide acetate for the treatment of several types of neuroendocrine and adrenal tumors including neuroendocrine tumors of the pancreas, neuroendocrine tumors of the gastrointestinal tract, lung, and thymus (carcinoid tumors), pheochromocytoma/paraganglioma, and thymomas and thymic carcinomas. The NCCN Palliative Care Guidelines recommend octreotide for the treatment of malignant bowel obstruction.\(^3\)

Clinical evidence supports the use of octreotide acetate for the treatment of chemotherapy and/or radiation-induced diarrhea,\(^3-7\) for refractory HIV/AIDS-related diarrhea that does not respond to first-line anti-diarrheal therapy,\(^8-16\) and as an adjunct to endoscopic therapy for bleeding gastroesophageal varices associated with liver disease.\(^17-22\)

2. **Coverage Criteria:**

Confidential and Proprietary, © 2019 UnitedHealthcare Services Inc.
A. Acromegaly

1. Initial Authorization

   a. Sandostatin will be approved based on both of the following criteria:

      (1) Diagnosis of acromegaly

      -AND-

      (2) One of the following:

             (a) Inadequate response to one of the following:

                 i. Surgery
                 ii. Radiotherapy
                 iii. Dopamine agonist (e.g., bromocriptine, cabergoline) therapy

             -OR-

             (b) Not a candidate for any of the following:

                 i. Surgery
                 ii. Radiotherapy
                 iii. Dopamine agonist (e.g., bromocriptine, cabergoline) therapy

      Authorization will be issued for 12 months.

2. Reauthorization

   a. Sandostatin will be approved based on the following criterion:

      (1) Documentation of positive clinical response to Sandostatin therapy

      Authorization will be issued for 12 months.

B. Meningioma

1. Initial Authorization

   a. Sandostatin will be approved based on all of the following criteria:

      (1) Diagnosis of meningioma

Confidential and Proprietary, © 2019 UnitedHealthcare Services Inc.
2. **Reauthorization**

   a. **Sandostatin** will be approved based upon the following criterion:

      (1) Patient does not show evidence of progressive disease while on Sandostatin therapy

      **Authorization will be issued for 12 months.**

C. **Neuroendocrine and Adrenal Tumors**

   1. **Initial Authorization**

      a. **Sandostatin** will be approved based on diagnosis of **one** of the following:

         (1) Neuroendocrine tumors [e.g., carcinoid tumors, Islet cell tumors, gastrinomas, glucagonomas, insulinomas, lung tumors, somatostatinomas, tumors of the pancreas, GI tract, lung and thymus, adrenal glands, and vasoactive intestinal polypeptidomas (VIPomas)]

            **-OR-**

         (2) **All** of the following:
(a) Diagnosis of Pheochromocytoma or Paraganglioma
(b) Disease is locally unresectable or distant metastases
(c) Disease is somatostatin receptor positive
(d) Presence of symptomatic disease

**Authorization will be issued for 12 months.**

2. **Reauthorization**
   a. **Sandostatin** will be approved based upon one of the following criteria:
      
      (1) Patient does not show evidence of progressive disease while on Sandostatin therapy
      
      -OR-
      
      (2) Documentation of positive clinical response (e.g. suppression of severe diarrhea, flushing etc.) to sandostatin therapy

      **Authorization will be issued for 12 months.**

D. **Thymoma or Thymic Carcinoma**

1. **Initial Authorization**
   a. **Sandostatin** will be approved based on the following criterion:
      
      (1) Diagnosis of thymoma or thymic carcinoma
      
      -AND-
      
      (2) Used as a second-line therapy for one of the following:

      (a) Unresectable disease following first-line chemotherapy for potentially resectable locally advanced disease, solitary metastasis, or ipsilateral pleural metastasis
      
      -OR-
      
      (b) Extrathoracic metastatic disease

      **Authorization will be issued for 12 months.**

2. **Reauthorization**
a. **Sandostatin** will be approved based upon the following criterion:

   (1) Patient does not show evidence of progressive disease while on Sandostatin therapy

**Authorization will be issued for 12 months.**

E. **Malignant Bowel Obstruction**

1. **Initial Authorization**

   a. **Sandostatin** will be approved based on the following criterion:

   (1) Diagnosis of malignant bowel obstruction

   **-AND-**

   (2) Gut function cannot be maintained

   **Authorization will be issued for 12 months.**

2. **Reauthorization**

   a. **Sandostatin** will be approved based upon the following criterion:

   (1) Documentation of positive clinical response to Sandostatin therapy

   **Authorization will be issued for 12 months.**

F. **Chemotherapy- and/or Radiation-Induced Diarrhea**

1. **Initial Authorization**

   a. **Sandostatin** will be approved based on the following criterion:

   (1) Diagnosis of diarrhea due to concurrent cancer chemotherapy and/or radiation

   **-AND-**

   (2) **One** of the following:

   (a) Presence of Grade 3 or 4 severe diarrhea
(b) Patient is in palliative or end of life care

Authorization will be issued for 12 months.

2. **Reauthorization**

   a. **Sandostatin** will be approved based on the following criterion:

      (1) Documentation of positive clinical response to Sandostatin therapy

          Authorization will be issued for 12 months.

**G. HIV/AIDS-Related Diarrhea**

1. **Initial Authorization**

   a. **Sandostatin** will be approved based on the following criterion:

      (1) Diagnosis of HIV/AIDS-related diarrhea

          Authorization will be issued for 12 months.

2. **Reauthorization**

   a. **Sandostatin** will be approved based on the following criterion:

      (1) Documentation of positive clinical response to Sandostatin therapy

          Authorization will be issued for 12 months.

**H. Bleeding Gastroesophageal Varices**

1. **Initial Authorization**

   a. **Sandostatin** will be approved based on the following criterion:

      (1) Diagnosis of bleeding gastroesophageal varices associated with liver disease

          Authorization will be issued for 12 months.

2. **Reauthorization**
a. **Sandostatin** will be approved based upon the following criterion:

   (1) Documentation of positive clinical response to Sandostatin therapy

**Authorization will be issued for 12 months.**

I. **NCCN Recommended Regimens**

1. **Initial Authorization**

   a. **Sandostatin** will be approved for uses not outlined above if supported by The National Comprehensive Cancer Network (NCCN) Drugs and Biologics Compendium.

**Authorization will be issued for 12 months.**

2. **Reauthorization**

   a. **Sandostatin** will be approved based on the following criterion:

   (1) Documentation of positive clinical response to Sandostatin therapy

**Authorization will be issued for 12 months.**

3. **References:**


Confidential and Proprietary, © 2019 UnitedHealthcare Services Inc.

7


<table>
<thead>
<tr>
<th>Program</th>
<th>Prior Authorization - Sandostatin® (octreotide acetate)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Change Control</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Date</strong></td>
<td><strong>Change</strong></td>
</tr>
<tr>
<td>12/2012</td>
<td>New clinical policy</td>
</tr>
<tr>
<td>3/2015</td>
<td>Template updated For acromegaly, removed radiotherapy and dopamine agonists as treatments that patients must not be a candidate for before approval. Changed Chemotherapy Induced Diarrhea criteria section to now include radiation induced diarrhea. Removed tincture of opium as an example of a standard therapy for diarrhea. Added new section for off-label use of sandostatin for the treatment of carcinoid tumor based on NCCN recommendation. Background and references updated.</td>
</tr>
<tr>
<td>9/2016</td>
<td>Updated clinical criteria to align with E&amp;I, including removing Sandostatin LAR from policy. Updated policy template.</td>
</tr>
<tr>
<td>9/2017</td>
<td>Annual review. Updated criteria for meningioma and neuroendocrine tumors. Updated references.</td>
</tr>
<tr>
<td>9/2018</td>
<td>Revised coverage criteria based on NCCN guidelines. Added NCCN Recommended Regimen review criteria. Updated references.</td>
</tr>
</tbody>
</table>

Confidential and Proprietary, © 2019 UnitedHealthcare Services Inc.
9/2019  Updated background and criteria to align with NCCN guidance.
       Updated references.